Vaniqa (Eflornithine)

Vaniqa (eflornithine hydrochloride) is a prescription cream used to slow the growth of unwanted facial hair in women. As a hair growth inhibitor, it works by blocking an enzyme that hair needs to grow, which helps reduce how fast new hair appears. The cream is applied to the face and the area just under the chin.

Directions

Vaniqa is used on areas of the face and under the chin where unwanted hair grows. Apply a thin layer to the affected skin twice a day, at least 8 hours apart.

Make sure the skin is clean and completely dry before use. If you have shaved, plucked, or waxed, wait at least 5 minutes before applying to reduce irritation. After applying Vaniqa, do not wash the area for 4 hours. You may apply makeup or sunscreen once the cream has dried.

Vaniqa must be used regularly and continuously along with normal hair-removal methods. It slows new hair growth but does not remove hair that is already there.

Ingredients

The active ingredient in Vaniqa is eflornithine.

Cautions

Before using this medication, you may want to consult a healthcare provider about the following:

• Any existing health conditions
• Any allergies
• A list of all medications currently being taken

Vaniqa is for external use on the skin only and should be stopped if you develop signs of an allergic reaction, such as swelling, rash, or severe irritation.

Improvement is usually seen after about 4 to 8 weeks of regular use, but hair growth typically returns to previous levels within about 8 weeks after stopping the cream.

Mild stinging, burning, or irritation can happen, especially if the cream is applied to broken or irritated skin. If irritation occurs, using it less often may help, but ongoing irritation means the product should be stopped.

Vaniqa should only be applied to intact skin, and contact with cuts or abrasions may increase discomfort.

It is not known whether Vaniqa interacts with other topical products, so caution is advised when using multiple creams on the same area.

Animal studies did not show an increased risk of skin cancer, genetic damage, or fertility problems when Vaniqa was used on the skin, and absorption into the body is very low.

The safety of Vaniqa during pregnancy is not well established, and its use during pregnancy should be carefully weighed against potential risks, with many experts recommending avoiding use if pregnant.

It is not known whether Vaniqa passes into breast milk, so caution is advised for people who are breastfeeding.

Vaniqa has not been shown to be safe or effective in children under 12 years of age.

Older adults have not shown increased safety concerns compared to younger users in clinical studies.

Contraindications

Avoid taking or using this medication if any of the following apply:

• History of sensitivity to eflornithine hydrochloride
• Known hypersensitivity to any components or excipients in the cream formulation
• Allergic reactions to similar topical medications

Side Effects

Common side effects of Vaniqa include:

• Skin stinging or burning
• Itching or tingling at the application site
• Redness or skin irritation
• Acne
• Ingrown hairs or razor bumps (pseudofolliculitis)
• Dry skin
• Rash

These side effects are usually limited to the treated skin area and are generally mild. Stinging, burning, or tingling may occur right after application, especially during the first weeks of use. Many people find these reactions improve as the skin adjusts to treatment.

Less common side effects can include folliculitis, headache, dizziness, nausea, or mild facial swelling. Rare skin reactions such as contact dermatitis, lip swelling, numbness, rosacea, or herpes simplex infections have been reported.

Contact a healthcare provider if skin reactions are severe, persistent, or worsening.